The online version of this article (doi:10.1186/1756-8722-7-14) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
All authors contributed to the conception and design of this review, participated in the drafting of the manuscript, and approved its final version.
Tumor behavior is not entirely determined by tumor cells. Studies have demonstrated that a variety of non-tumor cells in the tumor microenvironment affect tumor behavior; thus, a new focus of cancer research has been the development of novel cancer treatment ideas and therapeutic targets based on the effects of these cells. Mesenchymal stem cells (MSCs) are an important component of the tumor microenvironment; however, previous studies have produced controversial results regarding whether MSCs promote or inhibit tumor growth and progression. In particular, Naïve MSCs and tumor-derived MSCs (T-MSCs) have different functions. Naïve MSCs could exert bidirectional effects on tumors because these cells can both promote and inhibit tumor progression while T-MSCs promote tumor progression due to influences from the tumor itself and from the inflammatory tumor microenvironment. As an unhealed wound, tumor produces a continuous source of inflammatory mediators and causes aggregation of numerous inflammatory cells, which constitute an inflammatory microenvironment. Inflammatory factors can induce homing of circulating MSCs and MSCs in adjacent tissues into tumors, which are then being “educated” by the tumor microenvironment to support tumor growth. T-MSCs could recruit more immune cells into the tumor microenvironment, increase the proportion of cancer stem cells and promote tumor angiogenesis, further supporting tumor progression. However, as plasti city is a fundamental feature of MSCs, MSCs can also inhibit tumors by activating various MSC-based signaling pathways. Studies of the mechanisms by which interactions among tumors, MSCs, and the inflammatory microenvironment occur and methods to disrupt these interactions will likely reveal new targets for cancer therapy.
Al-Zoubi M, Salem AF, Martinez-Outschoorn UE, Whitaker-Menezes D, Lamb R, Hulit J: Creating a tumor-resistant microenvironment: cell-mediated delivery of TNFalpha completely prevents breast cancer tumor formation in vivo. Cell Cycle. 2013, 12 (3): 480-490. 10.4161/cc.23370. PubMedCentralCrossRefPubMed
Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR: BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013, 19 (5): 1225-1231. 10.1158/1078-0432.CCR-12-1630. PubMedCentralCrossRefPubMed
D’Souza N, Burns JS, Grisendi G, Candini O, Veronesi E, Piccinno S: MSC and Tumors: Homing, Differentiation, and Secretion Influence Therapeutic Potential. Adv Biochem Eng Biotechnol. 2012, Epub ahead of print, doi:10.1007/10_2012_150.
Pontikoglou C, Kastrinaki MC, Klaus M, Kalpadakis C, Katonis P, Alpantaki K: Study of the quantitative, functional, cytogenetic, and immunoregulatory properties of bone marrow mesenchymal stem cells in patients with B-cell chronic lymphocytic leukemia. Stem Cells Dev. 2013, 22 (9): 1329-1341. 10.1089/scd.2012.0255. PubMedCentralCrossRefPubMed
Xu S, Evans H, Buckle C, De Veirman K, Hu J, Xu D: Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia. 2012, 26 (12): 2546-2549. 10.1038/leu.2012.126. CrossRefPubMed
Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N: p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1alpha-mediated down-regulation of CXCL12. Blood. 2011, 118 (16): 4431-4439. 10.1182/blood-2011-02-334136. PubMedCentralCrossRefPubMed
Luo J, Ok Lee S, Liang L, Huang CK, Li L, Wen S: Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene. 2013, Epub ahead of print. doi:10.1038/onc.2013.233.
Teo GS, Ankrum JA, Martinelli R, Boetto SE, Simms K, Sciuto TE: Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-alpha-activated endothelial cells via both leukocyte-like and novel mechanisms. Stem Cells. 2012, 30 (11): 2472-2486. 10.1002/stem.1198. PubMedCentralCrossRefPubMed
Gao H, Priebe W, Glod J, Banerjee D: Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Stem Cells. 2009, 27 (4): 857-865. 10.1002/stem.23. CrossRefPubMed
Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL: The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A. 2009, 106 (10): 3806-3811. 10.1073/pnas.0900244106. PubMedCentralCrossRefPubMed
Hernanda PY, Pedroza-Gonzalez A, van der Laan LJ, Broker ME, Hoogduijn MJ, Ijzermans JN: Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma. Carcinogenesis. 2013
Tsukamoto S, Honoki K, Fujii H, Tohma Y, Kido A, Mori T: Mesenchymal stem cells promote tumor engraftment and metastatic colonization in rat osteosarcoma model. Int J Oncol. 2012, 40 (1): 163-169. PubMed
Bhattacharya SD, Mi Z, Talbot LJ, Guo H, Kuo PC: Human mesenchymal stem cell and epithelial hepatic carcinoma cell lines in admixture: concurrent stimulation of cancer-associated fibroblasts and epithelial-to-mesenchymal transition markers. Surgery. 2012, 152 (3): 449-454. 10.1016/j.surg.2012.06.011. PubMedCentralCrossRefPubMed
Razmkhah M, Jaberipour M, Erfani N, Habibagahi M, Talei AR, Ghaderi A: Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-beta1 and upregulate expression of regulatory molecules on T cells: do they protect breast cancer cells from the immune response?. Cell Immunol. 2011, 266 (2): 116-122. 10.1016/j.cellimm.2010.09.005. CrossRefPubMed
Montesinos JJ, Mora-Garcia Mde L, Mayani H, Flores-Figueroa E, Garcia-Rocha R, Fajardo-Orduna GR: In vitro evidence of the presence of mesenchymal stromal cells in cervical cancer and their role in protecting cancer cells from cytotoxic T cell activity. Stem Cells Dev. 2013, 22 (18): 2508-2519. 10.1089/scd.2013.0084. PubMedCentralCrossRefPubMed
Cho JA, Park H, Lim EH, Lee KW: Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int J Oncol. 2012, 40 (1): 130-138. PubMed
Cheng J, Li L, Liu Y, Wang Z, Zhu X, Bai X: Interleukin-1alpha induces immunosuppression by mesenchymal stem cells promoting the growth of prostate cancer cells. Mol Med Rep. 2012, 6 (5): 955-960. PubMed
Shin SY, Nam JS, Lim Y, Lee YH: TNFalpha-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. J Biol Chem. 2010, 285 (40): 30731-30740. 10.1074/jbc.M110.128124. PubMedCentralCrossRefPubMed
Cho JA, Park H, Lim EH, Kim KH, Choi JS, Lee JH: Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol Oncol. 2011, 123 (2): 379-386. 10.1016/j.ygyno.2011.08.005. CrossRefPubMed
- The roles of mesenchymal stem cells in tumor inflammatory microenvironment
Robert Chunhua Zhao
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II